Reliable data on the frequency and clinical manifestations of LRRK2-related PD are particularly crucial at this juncture, as the PD field moves towards more targeted selection or stratification of patients for biomarker studies49, and trials of novel genetics-informed therapies5,8,9,50,51. This evidence concerns the gene LRRK2 and Parkinson disease.